Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2009

View Archived Issues

FYX-051 shows potent serum uric acid-lowering activity in rats

AstraZeneca reports results from third quarter of 2009

Dainippon Sumimoto reports results from Q2 of the year ending March 31, 2010

Analyses of phase III data detail activity of fidaxomicin against C. difficile infection

AST-120 improves pruritus in patients with chronic liver disease

ITMN-191 monotherapy for HCV infection correlates with high barrier to viral escape

BMS-650032 shows potent anti-HCV activity in two phase II trials

Schering-Plough claims gamma-secretase modulators for AD therapy

arGentis to initiate first-in-human clinical trial of ARG-301 in rheumatoid arthritis

Adeona launches CopperProof Test for AD and cognitive impairment

PulmoBind has potential to diagnose conditions affecting pulmonary circulation

Pikamab to customize cancer antibody therapies with ADCC Therasight

Hybrigenics to meet with EMEA to discuss phase II trial of inecalcitol

Astex Therapeutics and GSK enter into strategic drug discovery alliance

Clinuvel to file MAA with EMEA for its photoprotective drug afamelanotide

Diamyd Medical completes enrollment in a phase III trial of Diamyd

First patient treated in phase IIb trial of 4SC-101 in rheumatoid arthritis

Bristol-Myers Squibb and Alder Biopharmaceuticals enter global RA biologic agreement

Avanir presents safety and efficacy data from STAR trial of Zenvia in PBA

Novel PI3K and mTOR inhibitors described by Wyeth as oncolytics

Novartis developing novel protease inhibitors for AD and other conditions

Merck KGaA reports dual-acting 5-HT reuptake inhibitors/5-HT1A receptor agonists

Phase I/II data show VIR-576 to be safe and effective in HIV

Promising preclinical and phase IIa data on S/GSK-1349572 disclosed

Bristol-Myers Squibb to split off its holdings in Mead Johnson

Merck & Co. completes enrollment in phase III clinical trial of SCH-530348

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...